A Phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high‐risk medulloblastoma (protocol POG 9631): A report from the Children's Oncology Group
- 21 December 2016
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 64 (6)
Abstract
Background: Children with high‐risk medulloblastoma historically have had a poor prognosis. The Children's Oncology Group completed a Phase II study using oral etoposide given with radiotherapy followed by intensive chemotherapy.Procedure: Patients enrolled in the study had high‐risk disease defined as ≥1.5 cm2 of residual disease postsurgery or definite evidence of central nervous metastasis. All patients underwent surgery followed by radiotherapy. During radiation, the patients received oral etoposide (21 days on, 7 off) at an initial dose of 50 mg/m2 per day (treatment 1), which was reduced to 35 mg/m2 per day (treatment 2) due to toxicity. After radiotherapy, the patients received chemotherapy with three cycles of cisplatin and oral etoposide, followed by eight courses of cyclophosphamide and vincristine.Results: Between November 1998 and October 2002, 53 patients were accrued; 15 received treatment 1 and 38 treatment 2. Forty‐seven patients (89%) were eligible. Response to radiation was excellent, with 19 (40.4%) showing complete response, 24 (51.1%) partial response, and four (8.5%) no recorded response. The overall 2‐ and 5‐year progression‐free survival (PFS) was 76.6 ± 6% and 70.2 ± 7%, respectively. The 2‐ and 5‐year overall survival (OS) was 80.9 ± 6% and 76.6 ± 6%, respectively. Clinical response postradiation and PFS/OS were not significantly different between the treatment groups. There was a trend toward a difference in 5‐year PFS between those without and with metastatic disease (P = 0.072).Conclusions: Oral etoposide was tolerable at 35 mg/m2 (21 days on and 7 days off) when given during full‐dose irradiation in patients with high‐risk medulloblastoma with encouraging survival data.Keywords
Funding Information
- National Cancer Institute (U10CA09543, U10CA098413, U10CA180886, U10CA180899)
This publication has 20 references indexed in Scilit:
- Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961Neuro-Oncology, 2012
- Subgroup-specific structural variation across 1,000 medulloblastoma genomesNature, 2012
- Outcome of Children With Metastatic Medulloblastoma Treated With Carboplatin During Craniospinal Radiotherapy: A Children's Oncology Group Phase I/II StudyJournal of Clinical Oncology, 2012
- Novel mutations target distinct subgroups of medulloblastomaNature, 2012
- A Phase II Study of Preradiotherapy Chemotherapy Followed by Hyperfractionated Radiotherapy for Newly Diagnosed High-Risk Medulloblastoma/Primitive Neuroectodermal Tumor: A Report From the Children's Oncology Group (CCG 9931)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- High-dose radiotherapy to 78 Gy with or without temozolomide for high grade gliomasJournal of Neuro-Oncology, 2009
- Metastasis Stage, Adjuvant Treatment, and Residual Tumor Are Prognostic Factors for Medulloblastoma in Children: Conclusions From the Children's Cancer Group 921 Randomized Phase III StudyJournal of Clinical Oncology, 1999
- Chronic oral VP-16 for recurrent medulloblastomaPediatric Neurology, 1997
- Phase II study of 21 day schedule oral etoposide in childrenEuropean Journal of Cancer, 1997
- Response of recurrent medulloblastoma to low-dose oral etoposide.Journal of Clinical Oncology, 1996